Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Celldex Therapeutics Inc (NASDAQ: CLDX) closed at $25.6 in the last session, up 1.23% from day before closing price of $25.29. In other words, the price has increased by $1.23 from its previous closing price. On the day, 1.57 million shares were traded. CLDX stock price reached its highest trading level at $26.03 during the session, while it also had its lowest trading level at $25.09.
Ratios:
We take a closer look at CLDX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 13.01 and its Current Ratio is at 13.01. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Mizuho on October 21, 2025, initiated with a Outperform rating and assigned the stock a target price of $48. On October 13, 2025, Barclays started tracking the stock assigning a Underweight rating and target price of $25. On April 28, 2025, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $64.Canaccord Genuity initiated its Buy rating on April 28, 2025, with a $64 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 04 ’25 when Jimenez Freddy A. sold 4,166 shares for $29.09 per share. The transaction valued at 121,210 led to the insider holds 30,796 shares of the business.
FREDDY A JIMENEZ bought 4,166 shares of CLDX for $121,210 on Dec 04 ’25. On Nov 13 ’25, another insider, Wright Richard M., who serves as the Former Officer of the company, sold 49,298 shares for $24.00 each. As a result, the insider received 1,183,177 and left with 20,833 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 1701106560 and an Enterprise Value of 1120504448. For the stock, the TTM Price-to-Sale (P/S) ratio is 654.27 while its Price-to-Book (P/B) ratio in mrq is 2.84. Its current Enterprise Value per Revenue stands at 431.129 whereas that against EBITDA is -4.431.
Stock Price History:
The Beta on a monthly basis for CLDX is 1.21, which has changed by 0.0335083 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, CLDX has reached a high of $30.50, while it has fallen to a 52-week low of $14.40. The 50-Day Moving Average of the stock is -2.59%, while the 200-Day Moving Average is calculated to be 13.04%.
Shares Statistics:
According to the various share statistics, CLDX traded on average about 887.64K shares per day over the past 3-months and 905620 shares per day over the past 10 days. A total of 66.45M shares are outstanding, with a floating share count of 64.57M. Insiders hold about 2.82% of the company’s shares, while institutions hold 107.35% stake in the company. Shares short for CLDX as of 1764288000 were 8675509 with a Short Ratio of 9.77, compared to 1761868800 on 7509487. Therefore, it implies a Short% of Shares Outstanding of 8675509 and a Short% of Float of 15.42.
Earnings Estimates
Investors are keenly observing as 12.0 analysts analyze and rate. The current performance of Celldex Therapeutics Inc (CLDX) in the stock market.The consensus estimate for the next quarter is -$1.05, with high estimates of -$0.96 and low estimates of -$1.2.
Analysts are recommending an EPS of between -$3.24 and -$3.68 for the fiscal current year, implying an average EPS of -$3.58. EPS for the following year is -$4.41, with 10.0 analysts recommending between -$4.01 and -$4.87.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for CLDX’s current fiscal year. The highest revenue estimate was $7M, while the lowest revenue estimate was $1.4M, resulting in an average revenue estimate of $2.79M. In the same quarter a year ago, actual revenue was $7.02M
